The FDA granted approval for a modified dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla to reduce risk of brain swelling, aiming to increase physician adoption. Meanwhile, Dizal Pharmaceutical’s sunvozertinib (Zegfrovy) received accelerated FDA approval for metastatic non-small-cell lung cancer with EGFR exon 20 insertion mutations. Both decisions represent recent regulatory advances providing updated therapeutic options for patients with challenging indications.